Page last updated: 2024-11-05

bornaprine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bornaprine: beneficial effect in Parkinsonism due to inhibition of muscarinic or nicotinic transmission [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID30160
CHEMBL ID4297087
CHEBI ID135406
SCHEMBL ID924755
MeSH IDM0048189

Synonyms (12)

Synonym
bornaprine
3-(diethylamino)propyl 2-phenyl-2-norbornanecarboxylate
bornaprine (inn)
20448-86-6
D07302
CHEBI:135406
SCHEMBL924755
BDNMABJZSXTKAQ-UHFFFAOYSA-N
Q4946040
3-(diethylamino)propyl 2-phenylbicyclo[2.2.1]heptane-2-carboxylate
CHEMBL4297087
DTXSID20864944

Research Excerpts

Treatment

ExcerptReferenceRelevance
"The bornaprine treatment, at 2 or 4 mg day(-1) dosage, has been effective and safe to contrast hyperhidrosis, in the acute phase of spinal cord-injured patients. "( Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients.
Bertolotto, F; Losio, L; Massone, A; Moretto, S; Oggerino, C; Ottonello, M; Sergi, R, 2008
)
1.2

Pharmacokinetics

ExcerptReferenceRelevance
" The curves showed no obvious differences in their pharmacokinetic properties."( [The disposition of bornaprine hydrochloride in the rat. 1. Pharmacokinetics: synthesis, plasma level and elimination].
Hege, G; Neidlein, R; Pichler, B; Weymann, J, 1989
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (75.00)18.7374
1990's2 (12.50)18.2507
2000's1 (6.25)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.33 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (38.89%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other10 (55.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]